Stocks
Intra-Cellular Therapies (ITCI) R&D/CAPEX US GAAP (year values) |
|||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | CAGR 5 years ? | |||
| R&D/CAPEX, % | 12 725% | 24 663% | 27 275% | 17 316% | 66 967% | 28 881% | |||
| Changes by years, y/y, % | -21 054pp | +11 938pp | +2 612pp | -9 960pp | +49 652pp | +14.7% | |||
Intra-Cellular Therapies. R&D/CAPEX, %
Intra-Cellular Therapies. R&D/CAPEX, changes, pp
Intra-Cellular Therapies (ITCI) R&D/CAPEX US GAAP (quarter values) |
||||||||
| 2023Q3 | 2023Q4 | 2024Q1 | 2024Q2 | 2024Q3 | LTM ? | |||
| R&D/CAPEX, % | 15 504% | 5 077 400% | 106 006% | 9 600% | 28 881% | |||
| Changes by years, y/y, % | -12 936pp | +4 956 464pp | -5 903pp | |||||
| Changes by quarters, q/q, % | +5 061 896pp | -5 077 400pp | -96 405pp | |||||
